Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. - Wikidata - wikimedia - TriplyDB

Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma.

Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma.

http://www.wikidata.org/entity/Q36614705

about

The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy EGFR Signaling in Liver Diseases An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma Targeted Therapy in Biliary Tract Cancers The significance of genetics for cholangiocarcinoma development Cholangiocarcinoma Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies Progression of targeted therapy in advanced cholangiocarcinoma Molecular profiling of biliary tract cancer: a target rich disease HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials Targeting Angiogenesis in Biliary Tract Cancers: An Open Option ADAM-12 as a diagnostic marker for the proliferation, migration and invasion in patients with small cell lung cancer.A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma.The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.Genetic and molecular abnormalities in cholangiocarcinogenesis.Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines.Therapeutic options for intrahepatic cholangiocarcinoma The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer.Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.Recent advances in the regulation of cholangiocarcinoma growth Expression of epidermal growth factor receptor, p53, Bcl2, vascular endothelial growth factor, cyclooxygenase-2, cyclin D1, human epidermal receptor-2 and Ki-67: Association with clinicopathological profiles and outcomes in gallbladder carcinoma.Impaired degradation followed by enhanced recycling of epidermal growth factor receptor caused by hypo-phosphorylation of tyrosine 1045 in RBE cells.Systemic Therapy of Cholangiocarcinoma.Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.Pathological aspects of so called "hilar cholangiocarcinoma".Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma.Beclin 1 deficiency correlated with lymph node metastasis, predicts a distinct outcome in intrahepatic and extrahepatic cholangiocarcinoma.Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma CA9 overexpression is an independent favorable prognostic marker in intrahepatic cholangiocarcinoma.Molecular diagnosis of intrahepatic cholangiocarcinoma.Cholangiocarcinoma: Correlation between Molecular Profiling and Imaging Phenotypes.Chemotherapy outcomes for the treatment of unresectable intrahepatic and hilar cholangiocarcinoma: a retrospective analysis.HER2/neu-directed therapy for biliary tract cancer.Tumors of ampulla of Vater: A case series and review of chemotherapy options Metabolic Characteristics of Advanced Biliary Tract Cancer Using 18F-Fluorodeoxyglucose Positron Emission Tomography and Their Clinical Implications Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma.

P2860

Q26751224-951CE3FA-9385-4D29-A001-CCD62E67DB61 Q26767120-157EF219-2943-40FA-9697-2C18AC63E10C Q26771265-087AD72D-03C1-46CA-BC22-2EC9A949CF07 Q26784091-8FFDF595-FFD3-4DA5-9A3F-BF90539CD899 Q26798443-332B325C-1B42-4EFE-B17E-07B656B51DA9 Q26865749-C1B000F6-8276-4978-8186-4747A8032EFA Q27001694-36E30287-E75F-4097-87B5-7E11EC6DE05C Q27002547-6788F109-AE80-4874-A0BB-8595BE488965 Q27016150-0368209E-E12A-478C-98B3-0C455DC152CF Q28072275-136F48E2-D0C4-40CB-BBD5-EC3D3649D32A Q28078111-1974773A-19A7-4A6E-BCCF-08D0ADE8BF93 Q30318857-2E702EDC-936D-456F-B41C-27F250633BC7 Q30398807-AC8EDA12-8D93-4CBD-B4F8-104D0E88158C Q31148772-A80106A8-282C-4433-8BEF-02CDCD9E4C93 Q33411061-2F0B3D72-EE33-4161-8509-DF67941E547B Q33441341-E133DF6B-9BCA-4CB4-B153-F8EB2B08926A Q33570262-83C2D6B3-DA59-4E6B-94D2-E4ECE63F3668 Q33611056-217FD828-35F2-4B05-B44B-A3F98DCFF658 Q33621529-F1E4F490-22EF-495D-AC24-FBAA0E2F2AA2 Q33656860-DB6C4AE5-7660-44EF-A414-72A8DC980C3F Q33750719-3DC2E305-C16E-4FEA-B5A1-3A78D9AAEA27 Q33994814-BA818F5A-A488-46C7-BB4D-6CFE1CB8EE88 Q34180209-17D6FB7E-2251-4535-B9F9-C9B3C3FE9639 Q34271518-F2737334-CE42-4D74-A7A0-243934C86D9B Q34551877-21712F78-7D86-4396-8BDA-77BAC6ED8AD8 Q34764681-223A7CA3-5754-4F09-BB28-22C574B63286 Q34898080-6DAAA1A9-4A7D-44FE-8770-751EC0E4D9FE Q34978321-95B53B6C-F307-45C6-A61A-435EEA315924 Q35058487-AEE523F8-0B1B-43D6-A08B-25DF797DF606 Q35108386-1B5D774F-1C63-4E1D-8555-FF3D5971FFCA Q35145280-EEC6726F-7501-4A44-A97A-BB72E88F42A8 Q35592221-79FF2A50-FDA8-4B56-A118-AEA73572BA18 Q35710375-8B29008D-B121-4FC9-AE69-83D0BA44599B Q35715498-01F96ACC-DC7D-4460-A2CF-850D3BD609D7 Q35748129-69C23D1A-2344-4C4F-A251-EF68C841225F Q35854505-9D87968D-2520-4F18-A08B-75B4B31E95B9 Q35915703-1F378494-2E03-424F-A819-13AC0193FC3E Q36113790-63F869CC-0477-4E6D-9C0B-C5C7567FA44A Q36287599-214A827D-A624-4862-966E-75F236DF736E Q36376264-CB3A416B-82C7-48EF-8E11-0E0DB7277E96

P2860

Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma.

http://www.wikidata.org/entity/Q36614705

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Clinicopathological and progno ...... ression in cholangiocarcinoma.

@ast

Clinicopathological and progno ...... ression in cholangiocarcinoma.

@en

type

label

Clinicopathological and progno ...... ression in cholangiocarcinoma.

@ast

Clinicopathological and progno ...... ression in cholangiocarcinoma.

@en

prefLabel

Clinicopathological and progno ...... ression in cholangiocarcinoma.

@ast

Clinicopathological and progno ...... ression in cholangiocarcinoma.

@en

P1433

Q36614705-DE820626-FAE1-4D8A-BDB8-F6506C12A746

P1476

Q36614705-BF6EBCF5-B88F-4A56-81BD-D312AB3F9F4B

P2093

Q36614705-00E7D3B4-9FAF-4DF7-B8BB-93CC68401625

Q36614705-17191C27-96BE-462C-9199-924644185134

Q36614705-6042F9A0-5E9F-487A-AEAF-964FAE979FC1

Q36614705-772E6C7A-CDB8-4A89-A27D-A1E1010AC5DD

Q36614705-86CA057B-AC5D-4A08-9EA1-CD2529E0D707

Q36614705-BB9CAA8E-39FF-44CA-AEEB-27A7E92426E9

Q36614705-CA749F8E-23EB-41A3-A31F-B6D7D9C49DC5

Q36614705-F0DF7F4B-9EFD-40E8-A198-B1F4C4EB7B08

P2860

Q36614705-0632A29E-1A25-43D8-A95A-79F287FD7280

Q36614705-0D7CB681-4AD0-4F3A-8DDE-EF504D2C51EC

Q36614705-173B2C24-81CF-41CA-944A-A29AF784BFD4

Q36614705-20AE49E6-1C71-46CB-8503-FD725B4278C1

Q36614705-3591169D-8382-42A3-882E-7010F8D5B947

Q36614705-36D58854-6DB6-4F64-A12A-FCEC293DA5AD

Q36614705-3EEEC4BB-47DC-4652-B440-4851A7004F95

Q36614705-3F8FAE4C-0447-4006-8CDD-CB439C0133F8

Q36614705-47F76279-EBD2-4074-B76E-A7754374CF70

Q36614705-4A655A93-2E08-4525-8F92-9904F6A04877

P2888

Q36614705-352939D6-CC0F-43B5-B43E-A4350416B6E1

P304

Q36614705-4C846112-4053-4F35-BDD3-DDECB1FD853F

P31

Q36614705-1CFDBE06-1B2F-4B41-BD6D-A24AFCB888E7

P356

Q36614705-2BF3A180-36D4-439B-9E2E-A296274F29E9

P407

Q36614705-2C45E496-24D5-42C5-A832-65A2C31B2288

P433

Q36614705-08E81701-7640-40D4-B7E9-523E642D4396

P478

Q36614705-CDE78241-F7E0-4CF9-B259-0149E5C8D174

P577

Q36614705-B536C667-7E5F-4AA8-80A9-3E3A3B8B821D

P5875

Q36614705-80E948BF-D212-477F-A250-53FCE19A6D6D

P698

Q36614705-8B791C43-F685-4941-9446-7C9804E44C57

P921

Q36614705-67BEEE7E-2AF7-489D-B8AB-7FBEC80245B0

P932

Q36614705-303EA012-D9D6-4829-B194-25A3FD1F4D93

P356

P1433

British Journal of Cancer

P1476

Clinicopathological and progno ...... ression in cholangiocarcinoma.

@en

P2093

D Yoshikawa

http://www.w3.org/2001/XMLSchema#string

H Ojima

http://www.w3.org/2001/XMLSchema#string

M Iwasaki

http://www.w3.org/2001/XMLSchema#string

N Hiraoka

http://www.w3.org/2001/XMLSchema#string

S Hirohashi

http://www.w3.org/2001/XMLSchema#string

S Kasai

http://www.w3.org/2001/XMLSchema#string

T Kosuge

http://www.w3.org/2001/XMLSchema#string

T Shibata

http://www.w3.org/2001/XMLSchema#string

P2860

Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Untangling the ErbB signalling network

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

The ErbB signaling network: receptor heterodimerization in development and cancer

Histologic risk factors and clinical outcome in colorectal malignant polyp: a pooled-data analysis.

Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma.

Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report.

Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy.

Cholangiocarcinoma.

P2888

P304

418-425

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6604129

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P577

2007-12-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5762061

http://www.w3.org/2001/XMLSchema#string

P698

18087285

http://www.w3.org/2001/XMLSchema#string

P921

cholangiocarcinoma

P932

2361442

http://www.w3.org/2001/XMLSchema#string